LS Capital, Inc., on behalf of a client and unaffiliated investor in Diffusion Pharmaceuticals Inc. made an offer to acquire remaining shares of Diffusion Pharmaceuticals Inc. (NasdaqCM:DFFN) on October 17, 2022. The unsolicited offer was made to purchase 100% of Diffusion Pharmaceuticals' outstanding common stock not already owned by the client for $6.58 per share in cash.

LS Capital, Inc., on behalf of a client and unaffiliated investor in Diffusion Pharmaceuticals Inc. cancelled the acquisition of remaining shares of Diffusion Pharmaceuticals Inc. (NasdaqCM:DFFN) on October 25, 2022. The offer was rejected by Diffusion's Board on October 25, 2022.